AMPK has also been demonstrated to block cell cycle progression in GC cells at the G0/G1 phase by reducing the expressions of epidermal growth factor receptor (EGFR) and insulin-like growth receptor-1 (IGF-1R), dephosphorylating retinoblastoma (RB), and inhibiting cyclin D1, CDK4, and CDK6 [269]. This evidence concerns the gene EGFR and gastric cancer.